This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Intellipharmaceutics Announces Third Quarter 2013 Results

TORONTO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2013. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

The Company recorded a net loss for the three months ended August 31, 2013 of $2.0 million, or $0.10 per common share, compared with a net loss of $1.5 million, or $0.08 per common share, for the three months ended August 31, 2012. The net loss for the nine months ended August 31, 2013 was $5.2 million, or $0.27 per common share, compared with a net loss of $4.8 million, or $0.28 per common share, for the nine months ended August 31, 2012. The Company's increased net loss in the three months ended August 31, 2013, can be primarily attributed to the increase in fair value adjustment of derivative liability of $0.2 million compared to a decrease in fair value adjustment of derivative liability of $0.5 million in the comparable 2012 period. After adjusting for the fair value adjustment of derivative liability, the loss for the three months ended August 31, 2013 and 2012 were both $1.9 million and are discussed below.

Loss from operations for the three months ended August 31, 2013 was $1.7 million compared with $2.1 million for the three months ended August 31, 2012. Research and development expense for the three months ended August 31, 2013 decreased to $1.0 million compared to $1.3 million in the three months ended August 31, 2012. After adjusting for stock-based compensation expense, expenditures for research and development for the three months ended August 31, 2013 were lower by $0.2 million. Selling, general and administrative expenses for the three months ended August 31, 2013 were $0.6 million versus $0.7 million in the prior period. After adjusting for stock-based compensation expense, expenditures for selling, general and administrative expenses for the three months ended August 31, 2013 were lower by $0.1 million.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs